ÜBERNAHMEANGEBOT für Ibex Techs. (TSX:IBT) WPKN:883396 - 500 Beiträge pro Seite

[stupidgame]

Bieter ist Miraculins Inc. (TSXV:MOM)
Das Gebot beinhaltet einen Aktientausch: 1 Miraculins für 5 Ibex. Tauschangebot bewertet die Ibex-Aktie mit 0,182 Can$. Entspricht aktuell 0,1244€.
Aktie wird in FF, STU und BER gehandelt. Ask`s dort zur Zeit zwischen 0,09 und 0,095€ !

Hier die Meldung von gestern, nachbörslich.

MIRACULINS INC



Miraculins Announces Offer to Combine With IBEX Technologies Inc.
11/16/2006

- Transaction represents a 65% premium for IBEX shareholders based on 50 day average closing price

WINNIPEG, MANITOBA, Nov 16, 2006 (MARKET WIRE via COMTEX News Network) --
Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announced that it intends to make an unsolicited offer to acquire all outstanding common shares of IBEX Technologies Inc. (TSX: IBT). IBEX is a Montreal-based biotechnology company focused on the development of diagnostics for the management of cancer and arthritis. This offer follows a direct approach by Miraculins to IBEX's management and Board of Directors.

Under the terms and conditions of the offer, Miraculins has proposed the two companies be combined on the basis that the current IBEX shareholders receive one common share of Miraculins (as the combined company) for every five shares of IBEX that they currently hold. Upon completion of the merger, Miraculins shareholders would own approximately 77% percent and IBEX shareholders would own approximately 23% percent of the combined company. This offer represents a deemed value of $0.182 for IBEX shareholders, a 65% premium over the average closing price of IBEX common shares on the Toronto Stock Exchange for the past 50 days of trading. On November 15, 2006 the average closing price for the past 50 days of each IBEX common share was $0.11 on the Toronto Stock Exchange and the average closing price for the past 50 days of each Miraculins common share was $0.91 on the TSX Venture Exchange.

"The cancer diagnostic programs of Miraculins and IBEX are extremely complementary, and future opportunities for our companies are enhanced by this transaction", said Dr. Jim Charlton, President of Miraculins Inc. "We believe that this offer represents an attractive value for the shareholders of IBEX and Miraculins, and is consistent with our strategy to focus on building a strong biomarker company and driving shareholder value."

Documents relating to the offer are expected to be made available to shareholders of IBEX as soon as practicable. Completion of the offer is subject to various terms and conditions as will be outlined in the formal takeover bid offer.

This offer will be made only by a separate formal offer and takeover bid circular. This news release does not constitute an offer of solicitation in any jurisdiction. Any such offer or solicitation will be made only by formal offer and only in jurisdictions where Miraculins may legally do so.

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's BEST(TM) Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

This press release contains forward-looking statements. All statements, other than statements of historical fact, included herein are forward-looking statements that involve risks and uncertainties. There can be no assurances that such statements will prove to be accurate, and actual results in future events could differ materially from those anticipated in such statements. Important factors that could cause actual statements to differ materially from Miraculins' expectations are disclosed in those documents filed from time-to-time with applicable securities regulatory authorities in Canada.

Readers are cautioned not to rely on these forward-looking statements. Miraculins does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise except as required by law.

The following factors related to the business combination of Miraculins and IBEX could cause actual results to differ materially from the forward-looking statements: lack of Shareholder support for the Offer; the timing of the closing of the transaction, if approved by Shareholders; dilution; the businesses of Miraculins and IBEX may not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; changes in management and organizational structure; and the expected combination benefits from the Miraculins/IBEX transaction may not be fully realized nor realized within the expected time frame.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contacts: Miraculins Inc. Christopher J. Moreau Vice President, Business Development [phone] [phone] (FAX) Email: [e-mail] Website: www.miraculins.com

SOURCE: Miraculins Inc.

mailto:[e-mail] http://www.miraculins.com

Copyright 2006 Market Wire, All rights reserved.


Hier die Links zu beiden Aktien

http://www.stockhouse.com/comp_info.asp?symbol=IBT&table=lis…
http://www.stockhouse.com/comp_info.asp?symbol=MOM&table=Lis…

Die Meldung steht unten auf der jeweiligen Seite.

[ycbm]

habe mich mal positioniert.

lt. stockhouse.ca soll IBEX 0,19$/ share in cash haben...und 2mio$ umsatz im jahr. der dotige user glaubt an eine feindliche übernahme


IBT Company Snapshot
BullBoards Member Forums My BullBoards


Jump to IBT Forum


SUBJECT: $0.182/sh takeover offer is inadequate Posted By: lscfa
Post Time: 11/16/2006 20:48
« Previous Message Next Message »

Miraculins' takeover offer of $0.182/share for IBT is opportunistic.
At last quarter end IBEX had $0.19 per share in cash, $2 million in annual revenues and valuable patented technology.

IBT's management is sure to view this as a hostile takeover.



NewsBlast Sign-Up
StockHouse NewsBlast: Receive company sponsored news and information via email.





This message (Post #13591843) has been viewed 9 times
Report a BullBoards Violation Ignore lscfa Post Reply View Threads
Go to
BullBoard: Symbol Company Name
Search by
Post ID:


9 Red Flags to Help Spot Message Board Scammers | BullBoards Abbreviations


denke das sich der kurs dem angebot gegen 15.30 nähern wird. vielleicht erwartet der markt noch mehr und der kurs geht auf 0,20$...


auf jedenfall ein zock wert...


ycbm

[stupidgame]

Antwort auf Beitrag Nr.: 25.484.223 von ycbm am 17.11.06 14:00:43

Danke für die Info. Hört sich sehr gut an. Ich hatte das weiter noch gar nicht recherchiert. Habe aber erstmal auch eine Kauforder in Toronto zu stehen. Mal sehen, vielleicht pennen die noch zu Handelsbeginn, und es lässt sich noch was abstauben.

Gruss
s.

[stupidgame]

Antwort auf Beitrag Nr.: 25.484.370 von stupidgame am 17.11.06 14:10:10

Vorbörslich, von 14:01 Uhr steht sie schonmal 0,13 (50.000)/0,13(29.000)

[ycbm]

hier kleiner auszug aus den zahlen per 09.06.2006
cashposition am ende des auszuges



Ibex Reports Sales Revenue Increase of 23% for the Quarter and 33% for the Nine Month Period
09:15 EDT Friday, June 09, 2006


MONTREAL, QUEBEC--(CCNMatthews - June 9, 2006) - IBEX Technologies Inc. (TSX:IBT), an innovator in the development of diagnostics for the management of cancer and arthritis, and a supplier of high-purity glycobiology enzymes, today reported its financial results for the third quarter and nine-months ended April 30, 2006.

Paul Baehr, President and Chief Executive Officer, commented on the successful financial period, "Our higher product revenue for this past nine months of over $1.5 million is close to our entire product sales for the previous year, due to a continued increase in demand from pharmaceutical and medical device companies for our enzyme reagents and diagnostic assays and from the continuing growth of the glycobiology enzymes."



During the third quarter, IBEX reported on the following events:


- Further strengthening its intellectual property portfolio, IBEX
received notice of allowance in May 2006 from the European Patent
Office on the human kallikrein 15 (hK15) patent, which is
licensed to IBEX from Mt. Sinai Hospital in Toronto. The patent
has broad claims covering the gene and protein for therapeutic
and diagnostic use. Corresponding patent applications have been
filed in the United States and Canada.


- The Company reported on the results of a rheumatoid arthritis
(RA) clinical study confirming the utility of the IBEX's serum
biomarkers for measuring degradation and synthesis of cartilage.
This important study was published in the peer-reviewed journal,
Arthritis Research and Therapy (8: R31, January 2006).


The lead author, Dr. Suzan Verstappen, Department of Rheumatology
and Clinical Immunology, University Medical Center Utrecht, the
Netherlands commented that the use of these biomarkers may be of
value when studying progression of joint damage in patients with
rheumatoid arthritis. This study was important in confirming the
predictive utility of IBEX's biomarker assays for monitoring RA
disease progression and aligns with continued increased sales for
the Company's arthritis products from leading pharmaceutical
companies.


- The Company also submitted an abstract on IBEX's biomarkers for
possible presentation at the American College of Rheumatology's
70th Annual Scientific Meeting in Washington, DC to be held
November 10-15, 2006. This abstract contained important
scientific results relating to the use of certain IBEX biomarkers
in urine.


- To increase awareness of the Company to investors, IBEX
participated in several key financial and industry conferences in
the US, Canada and Europe including BIO 2006, BioFinance Canada
2006 and the Rodman & Renshaw 3rd Annual Global Healthcare
Conference.


Additional milestones and events for the rest of the calendar year
include:


- Initiation of lung cancer study to evaluate IBEX kallikreins as
potential screening biomarkers in high risk lung cancer patients.
This study is expected to begin in the second half of 2006.


- Pursuit of licensing agreements for the development and
commercialization of several kallikrein cancer diagnostics.


- Release for sale of a new C2C urine assay and a new CP II ELISA kit
by the end of the calendar year (for use in biopharmaceutical
research and development).


- Expansion of existing agreements with major partners for Heparinase
I IBEX in point-of-care blood monitoring devices.


- Expansion of customer base for Heparinase I IBEX.


Subsequent to the end of the quarter the Company has decided not to advance its kallikrein therapeutic protein program. This decision was made as a result of the recent review of its latest preclinical data using the purified hk10 kallikrein. These data, while directionally positive, were not sufficient enough to warrant a continuation of the program by IBEX. This decision will reduce the Company's annual burn rate by more than $500,000 per year. The kallikrein diagnostic program is not affected by this decision and the Company continues to pursue what it believes are significant commercial opportunities in this area.

Financial Results

The unaudited interim consolidated financial statements are expressed in Canadian dollars. Solely for the convenience of the reader, selected financial results below have been translated into U.S. dollars at the April 2006 month-end rate C$1.00 equals US$0.8945. This translation should not be construed as an application of the recommendations relating to the accounting for foreign currency translation, but rather as supplemental information for the reader.

Sales revenue recorded for the three-month period ended April 30, 2006 totaled C$496,185 (US$444,000) compared to C$403,225 in the third quarter of fiscal 2005, representing an increase of 23 percent. IBEX's glycobiology enzyme and arthritis sales revenues increased by 38 percent and six percent respectively, over the same period last year.

Sales revenue for the nine-months ended April 30, 2006 totaled C$1,514,158 (US$1,354,000) versus C$1,138,963 for the same period in 2005, representing an increase of 33 percent.

The 23 percent increase in sales revenue for the quarter and the 33 percent increase for the nine-month period were primarily driven by a 37 percent increase in IBEX's high purity glycobiology enzymes and a 25 percent increase in arthritis sales revenue, over the same period last year.

Net loss for the third quarter of 2006 was C$854,461 (US$764,000) or C($0.04) per share, compared with a net loss of C$1.1 million or C($0.05) per share in the same period a year ago. The net loss for the nine-months ended April 30, 2006 was C$2.3 million (US$2.0 million) or C($0.10) per share compared to a net loss of C$3.1 million or C($0.15) per share for the same period in 2005. The Company's decreased net loss in both periods was mainly attributable to an increase in product revenues and a decrease in general and administrative expenses related to the company's successful defense against an unsolicited takeover attempt by a third party.

Research and development expenses for the third quarter of fiscal 2006 were C$581,479 (US$520,000) versus C$544,292 in the same period a year ago. For the nine-months ended April 30, 2006, R&D expenses at C$1,678,645 (US$1.5 million) were in-line with same period prior year expenses at C$1,616,519. The current year expenses for both the arthritis and cancer programs individually are in-line with the expenses for the same period last year.

Selling, general and administrative expenses and cost of goods sold for the third quarter of fiscal 2006 were C$745,494 (US$667,000) versus C$952,276 in the same period a year ago mainly due to higher business development expenses relating to a market research study in 2005 and a one-time severance payment made in the third quarter of fiscal year 2005.

Selling, general and administrative expenses and cost of goods sold for the nine-months ended April 30, 2006 totaled C$2.0 million (US$1.8 million) compared to C$2.6 million for the same period in fiscal 2005. The decrease in expenses is partially as explained in the paragraph just above and mainly due to the Company successfully defending a hostile takeover bid by an unsolicited third party during the second quarter of fiscal 2005 which caused the Company to incur C$400,000 in expenses.

IBEX's net cash burn was C$1.7 million over the nine-month period ended April 30, 2006. At April 30, 2006, IBEX cash, cash equivalents and marketable securities totaled C$5.5 million (US$4.9 million), and the Company's net working capital was C$4.8 million (US$4.3 million). The company believes it has adequate financial resources to support its current programs for at least 24 months.

About IBEX

IBEX is focused on the development of diagnostics for the management of cancer and arthritis. The Company's cancer program is based on a novel family of genes known as kallikreins. IBEX is developing kallikrein-based diagnostics for screening and monitoring cancer. The Company's arthritis program is based on a series of biomarkers of cartilage degradation and synthesis.

IBEX markets a number of products, including its high-purity proprietary enzymes (heparinases and chondroitinases), as well as a series of arthritis and kallikrein-based assays. Heparinase I IBEX is used in many leading hemostasis monitoring devices, while IBEX arthritis assays are used by leading pharmaceutical companies for research purposes. For more information, please visit the Company's Web site at www.ibex.ca.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.

TO THE SHAREHOLDERS OF IBEX TECHNOLOGIES INC.

The interim consolidated balance sheet of IBEX Technologies Inc. as of April 30, 2006 and the interim consolidated statements of loss and deficit and cash flows for the period then ended have not been reviewed by the Company's auditors, PricewaterhouseCoopers LLP. These financial statements are the responsibility of management and have been reviewed and approved by the Audit Committee.

[ycbm]

Antwort auf Beitrag Nr.: 25.484.594 von stupidgame am 17.11.06 14:22:25

ist aber nicht deine order oder????

[stupidgame]

Antwort auf Beitrag Nr.: 25.484.766 von ycbm am 17.11.06 14:32:38

Nee, ich wollte es eigentlich bischen billiger probieren.
Na, mal sehen.

[stupidgame]

Antwort auf Beitrag Nr.: 25.484.862 von stupidgame am 17.11.06 14:37:45

Jetzt 0,135/0,135.
Seit 14:30 habe ich auch den Live-Kurs.

[stupidgame]

Antwort auf Beitrag Nr.: 25.485.021 von stupidgame am 17.11.06 14:44:48

Jetzt 0,14/0,14

[ycbm]

Antwort auf Beitrag Nr.: 25.485.888 von stupidgame am 17.11.06 15:23:56

denke mal, das bei einer positiven eröffnung und starkem volumen die aktie sich dem übernahmeangebot angleichen sollte...
denn was als skepsis zurückhaltung untermauert sollte dann der tatsache ergebnis tragen...


mal schaun

[ycbm]

kannst du den RT-chart + volumenangabe von toronto hier reinstellen.

danke

[stupidgame]

Antwort auf Beitrag Nr.: 25.486.024 von ycbm am 17.11.06 15:29:38

Du, sowas habe ich noch nicht gemacht. Da muss man bei ADVFN sein, oder?
Ich kann Dir aber RT geben.
Bid:0,13(4000)
Ask:0,15(10000)
Last:0,135
Vol:75.080

[stupidgame]

Antwort auf Beitrag Nr.: 25.486.251 von stupidgame am 17.11.06 15:37:19

Bid:0,135(10.000)
Ask:0,145(4.000)
Last:0,13
Vol:79.080

Wenig los.

[ycbm]

ok. danke dir.

ist ADVFN eigentlich kostenlos inkl. RT-kurse???

danke dir schonmal vorab und hoffen wir mal das beste mit IBEX

[stupidgame]

Antwort auf Beitrag Nr.: 25.486.409 von ycbm am 17.11.06 15:43:15

ADVFN, glaube ich, ja.
Man muss aber registriert sein. Und da hat das bei mir ziemliches Durcheinander gegeben. Da ich eh RT-Streamer habe, habe ich das dann gelassen.

Bid:0,145(16.000)
Ask:0,15(10.000)
Last:0,145
Vol:83.580

[ycbm]

Antwort auf Beitrag Nr.: 25.486.556 von stupidgame am 17.11.06 15:47:52

ok.
welcher anbieter besitzt du für deine RT-Kurse von ausländischen kurse.
ich nutze mal otcbbtrader.com gab dann aber dort interne probleme, habe jetzt ne unterseite von advfn für eine aktie aber nicht für alles.
wäre von vorteil überall rt-kurse einsehen zu können

[stupidgame]

Antwort auf Beitrag Nr.: 25.486.705 von ycbm am 17.11.06 15:52:50

Für US-Kurse habe ich 2.
eSignal (9,95$/Monat)
Und meinen 2.Broker-Agora Direct. Über den bekomme ich auch Toronto.
Es gibt aber, glaub ich, bei eSignal auch USA/Kanada im Paket für 14,95$.

Quote ist immer noch unv.
Vol, jetzt: 92.580

[ycbm]

danke dir. sind ja humane gebühren.

dtschl taxt in stuttgart und berlin taxen weiter hoch...
spielt das volumen in can mit???

bin mal gespannt auf den sk in can...muß leider nachher weg und kann erst spät den kurs kontrollieren...

[stupidgame]

Antwort auf Beitrag Nr.: 25.486.852 von stupidgame am 17.11.06 15:58:24

BID:0,15(5.000)
ASK:0,165(6.000)
Last:0,165
Vol:106.080

[stupidgame]

Antwort auf Beitrag Nr.: 25.487.423 von stupidgame am 17.11.06 16:15:30

Jetz kehrt hier Ruhe ein - von den Umsätzen.
Bid:0,15(5.000)
Ask:0,16((8000)
Last:0,16
Vol:123.580

Scheint erstmal zu stoppen.

[ycbm]

Antwort auf Beitrag Nr.: 25.487.844 von stupidgame am 17.11.06 16:29:28

ok.
volumen in can ist aber im vergleich zu den vortagen schon recht ordentlich nach einer stunde.
naja mal schaun, sind ja noch mit 0,16$ 20% vom angebot entfernt...

[stupidgame]

Antwort auf Beitrag Nr.: 25.488.282 von ycbm am 17.11.06 16:43:55

Bis gegen Ende der Session scheint sich hier nicht mehr viel zu tun.
Bid:0,15(33.000)
Ask:0,165(7.000)
Last:0,15
Vol:151.080

Auffällig, kurz vor 17:00, glaub ich, gab es einen relativ starken Kauf des Übernehmers. Dort steht der Kurs jetzt bei 0,95. Vol:40.500

[stupidgame]

Antwort auf Beitrag Nr.: 25.490.676 von stupidgame am 17.11.06 17:53:13

Hier nochmal die aktuellsten Wasserstände aus Toronto.
Bid:0,155(2.000)
Ask:0,17(67.000)
Last:0,17
Vol:209.580

[stupidgame]

Antwort auf Beitrag Nr.: 25.493.332 von stupidgame am 17.11.06 19:14:06

Und die Schlusskurse
Bid:0,17(4.000)
Ask:0,175(16.000)
Last:0,17 (+78,95%)
Vol:310.280

[ycbm]

moin.
hat ja schön auf tageshoch geschlossen.volumen war auch recht ordentlich, wenn auch untypisch für nen übernahmezock...
pari mit 0,17$ macht 0,116€, also noch ca. 10% + bei uns. und im stockhouseforum wird die 0,20$ gehandelt...

0,20$ ergeben 0,136€...


ycbm

[ycbm]

hier noch ein auszug von nem teilnehmer mit ziel 0,60$


IBT Company Snapshot
BullBoards Member Forums My BullBoards


Jump to IBT Forum


SUBJECT: RE: target price Posted By: guarantor
Post Time: 11/17/2006 16:39
« Previous Message Next Message »

Interesting question...
You won't get a target price from a broker, because they don't follow it any more.

My target price....
As a long term holder
And there aren't too many of us left
And most of us have been Institutionalized or sold...
At least 60 cents.

I know it sounds crazy
BUT
20 cents cash per share
And only 4X sales of Arthritis and Enzymes gives you about another 40 cents.
And that is not even factoring in Cancer and Physical Plant.

60 cents minimum is my final answer..

Bottom line re target price depends on Lloyd down in Florida, and BVI out in San Fran. They own Boatloads, and I guess what they want for their shares, is the Target.

Darned if I know what they want



NewsBlast Sign-Up
StockHouse NewsBlast: Receive company sponsored news and information via email.

[ycbm]

0,60$ entsprechen 0,409€

das wäre cool...


ycbm

[ycbm]

habe ich auf der webseite gefunden

besonders der letzte teil ist sehr interessant. IBEX rät seinen aktionären, das angebot nicht einzugehen.
es wird nun nach dem weißen ritter gesucht, welcher eine kooperation mit IBEX eingeht und dies soll bis ende des jahres kompletiert werden...also hier ist noch viel musik drin.
realistisch sind 0,20CAN$, kursziele mit bis zu 0,50-0,60CAN$ werden sogar genannt. es waren 4,5mio$, denke mal CAN$, per 31.07.2006 in cash vorhanden. bei 23 mio aktien ergibt dies 0,20CAN$ kurswert...dazu kommen 2mio$ umsätze im jahr + weiteres potential...

allerdings wird dies nur ein zock für mich...mein finger ruht auf dem verkaufsknopf....




IBEX Technologies Inc.
5485 Paré, Montréal, Québec, Canada H4P 1P7
Tel.: [phone] • Fax: [phone]
Email: [e-mail]


IBEX RESPONSE TO UNSOLICITED OFFER FROM MIRACULINS INC.

MONTREAL, Quebec – November 17, 2006 – IBEX Technologies Inc. (TSX: IBT) announces
that Miraculins Inc. of Winnipeg, Manitoba (TSX VENTURE:MOM) has issued a press release
announcing its intention to make an unsolicited offer for all of IBEX’s outstanding common
shares. According to the press release, Miraculins proposes that the two companies be
combined, with current IBEX shareholders owning 23% of the combined company. IBEX
shareholders would receive one share of Miraculins (as the combined company) for every five
shares of IBEX that they currently own.

The Board of Directors of IBEX will appoint financial advisors when the Miraculins circular is
available and will thereafter make a recommendation to the IBEX shareholders.
The Board of Directors of IBEX notes initially that the value attributed to IBEX’s shares as
announced by Miraculins is approximately equal to the value of IBEX’s cash, cash equivalents
and marketable securities and gives no value to IBEX’s cancer diagnostic technology, or to
approximately $2 million in sales from IBEX’s growing specialty enzyme and arthritis kit
business. The IBEX Board notes that as at August 31, 2006, the date of its most recent financial
statements, Miraculins had only $1.6 million in cash and equivalents while IBEX reported cash
and equivalents of $4.5 million at July 31, 2006.
The IBEX Board also notes that Miraculins’ shares have declined in price by more than 50%
over the past six months, from approximately $1.80 in December 2005 to their current price of
$0.85, and that there is negligible trading volume.
IBEX advises its shareholders not to deposit any common shares of IBEX to the Miraculins offer
and to not take any action concerning the offer until shareholders have received further
communication from the Board of Directors of IBEX.
The IBEX Board also announces that it has entered into a non-binding letter of intent in
connection with a proposed acquisition by IBEX of a private company based in the Montreal
region, and expects to sign a definitive agreement before the end of 2006. If the acquisition is
concluded, it will substantially increase IBEX’s size. The potential acquisition by IBEX results
from IBEX’s previously-announced strategic initiatives to raise shareholder value. The object of
the proposed acquisition is to turn IBEX into a specialty pharmaceutical company with rapidly
growing sales. No assurance can be given by IBEX at this time that the proposed acquisition
will be completed.
About IBEX Technologies Inc.

IBEX is focused on the development of diagnostics for the management of cancer and arthritis.
The Company’s cancer program is based on a novel family of genes known as kallikreins, IBEX
is developing kallikrein-based diagnostics for screening and monitoring cancer. The Company’s
arthritis program is based on a series of biomarkers of cartilage degradation and synthesis.

IBEX markets a number of products, including its high-purity proprietary enzymes (heparinases
and chondroitinases), as well as a series of arthritis and kallikrein-based assays. Heparinase I
IBEX is used in many leading hemostasis monitoring devices, while IBEX arthritis assays are
used by leading pharmaceutical companies for research purposes. For more information, please
visit the Company’s web site at www.ibex.ca.


Safe Harbour Statement
All of the statements contained in this news release, other than statements of fact that are independently
verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the
current expectations of management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in
which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future results may differ materially
from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or
obligation to update these statements.


-30-

Contacts:
Paul Baehr Donna Lavoie
President & CEO Investor Relations
IBEX Technologies Inc. LaVoie Group
[phone] [phone] X103

[dahlmann14]

Antwort auf Beitrag Nr.: 25.528.717 von ycbm am 19.11.06 16:43:52

Vorbösliche Meldung:

Miraculins hat sein Übernahmeangebot für Ibex zurückgezogen. Ich fürchte, der Ibex-Kurs wird wieder auf das Niveau, das er vor dem Gebot hatte (c$ 0,10EUR 0,07) zurückfallen. Frankfurt taxt schon runter.

[Zockii]

ANUARY 30, 2007 - 10:30 ET

IBEX Signs Agreement for Acquisition of Garvinci Inc.

Positions IBEX as Specialty Pharmaceutical Company with Marketed Products in Arthritis and Women's Health

MONTREAL, QUEBEC--(CCNMatthews - Jan. 30, 2007) - IBEX Technologies Inc. (TSX:IBT) today announced that it has entered into an agreement for the acquisition of 100% of the shares of Garvinci Inc., a private Montreal firm with the Canadian distribution rights for a pipeline of arthritis and women's health products. One of these, an osteoarthritis product, is currently approved and being marketed by Garvinci in Canada, while a second, an emergency contraceptive pill has recently been approved and is expected to be introduced in the second quarter of 2007 through one of Canada's leading pharmaceutical companies.

Paul Baehr, President and Chief Executive Officer of IBEX, commented on the transaction: "This transaction is the first step in moving IBEX from a discovery and development company to a specialty pharmaceutical company focusing on acquiring marketing rights to already-approved products in Canada, and products which have been approved in other jurisdictions and which will be registered for sale in Canada. The Garvinci transaction will provide IBEX with an approved product, in one of our key target areas, osteoarthritis, and the recently-approved, morning-after pill (NorLevo®) for emergency contraception. This transaction is an outgrowth of our strategic review initiated in the summer of 2006".

Garvinci will become a wholly-owned subsidiary of IBEX and will be managed by Jean- Francois Gareau, President and founder of Garvinci. Mr. Gareau, Garvinci President said: "IBEX provides Garvinci with an experienced management team, an enlarged infrastructure and public market positioning that will be important for us as we continue our growth in the arthritis and women's health markets".

Details of the Transaction

As part of the transaction, IBEX will issue to the Garvinci shareholders on closing 15,333,333 new common shares, equal to 40% of the common shares that will be outstanding after the transaction, and 1,916,667 non-voting preferred shares. As a result, Mr. Gareau will become IBEX's largest shareholder. The non-voting preferred shares will be convertible into IBEX common shares on a one-for-one basis commencing one year from the date of closing. IBEX will also issue an additional 5,516,667 non-voting preferred shares to the Garvinci shareholders at closing, which will be convertible into IBEX common shares on a one-for-one basis upon the achievement of certain milestones by Garvinci. In addition, IBEX will pay $500,000 in cash on closing and will make additional payments to Garvinci shareholders in cash and/or shares upon the achievement by Garvinci of certain product-related approvals and sales milestones.

IBEX Technologies, Inc./Agreement for Acquisition of Garvinci, Inc.

As part of the transaction, IBEX has advanced $625,000 to Garvinci, to cover introductory marketing and other expenses. IBEX may extend other credit facilities to Garvinci prior to closing. In the event that the transaction does not close, any outstanding loans will be repaid by Garvinci at the earlier of: i) 12 months from the date discussions between the parties in connection with the transaction terminate, or ii) the date on which Garvinci enters into a business combination with a third party.

The closing of the transaction is subject to regulatory approval, including that of the Toronto Stock Exchange, IBEX shareholder approval, and the satisfaction of certain conditions by Garvinci. Closing is expected to occur in April 2007.

About Garvinci

Garvinci is a privately-held Canadian company focused on arthritis and women's health. The Company was founded in 2001 by Jean-Francois Gareau, a Montreal entrepreneur. Garvinci's principal assets are the Canadian distribution rights to a line of ostearthritis products and the Canadian distribution rights to the morning after pill NorLevo® from the French company, Laboratoire HRA Pharma S.A.

The osteoarthritis products include a visco-supplement product to relieve the symptomatic pain associated with osteoarthritis of the hip, shoulder and knee. The pipeline also includes an oral interleukin I inhibitor for the symptomatic relief of osteoarthritis which has been on the market in more than 20 countries and for which the Canadian filing for approval is expected in the next 24 months. Garvinci is also in discussions concerning Canadian rights to additional products such as a visco-supplement for smaller joint and a synovial fluid replacement product for relief of pain following arthroscopy.

Garvinci has received Notice of Compliance and a DIN number from Health Canada for the HRA Pharma product NorLevo®, a morning-after emergency contraceptive pill, and is currently in discussions with a senior pharmaceutical company to supplement Garvinci's marketing capabilities.

About IBEX

IBEX markets a number of products, including its high-purity proprietary enzymes (heparinases and chondroitinases), as well as a series of arthritis and kallikrein-based assays. IBEX Heparinase I is used in many leading hemostasis monitoring devices, while IBEX arthritis assays are used by leading pharmaceutical companies for research purposes.

As part of a strategic review initiated in the summer of 2006, IBEX decided to shift focus away from its traditional discovery and development model in favour of a revenue driven model.

The new IBEX will focus on acquiring rights to prescription products which are already approved in Canada or other jurisdictions. The Company will continue to benefit from its profitable specialty enzymes and arthritis assays business.

For more information, please visit the Company's web site at www.ibex.ca.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.

[Zockii]

Antwort auf Beitrag Nr.: 27.299.838 von Zockii am 30.01.07 17:13:53

warum bin ich gestern nach der Meldung nur nicht eingestiegen?

[jaegermaster]

Antwort auf Beitrag Nr.: 27.313.596 von Zockii am 31.01.07 09:47:36

Gute Frage!!
Ich hab die Meldung leider erst heute gesehen. Aber das wird wohl nicht das Ende der Fahnenstange gewesen sein.
Endlich geht´s wieder aufwärts!!